The reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIM-l) is an important target for drug therapy in the treatment of AIDS. Despite the recent successes, several of the most important anti-RT drugs are relatively toxic and all of them select for resistant variants of the virus. We believe that a better understanding of the structure and function of HIV-1 RT would be useful in the design of more effective inhibitors. This project is part of a larger collaborative effort to understand the mechanism(s) of drug resistance of HIV-1 RT. We will use recombinant DNA techniques to express both wild-type and mutant RT. Purified RT (both mutant and wild-type) will be prepared and used for biochemical, biophysical and structural analysis (the structural analysis will be done in the laboratory of Dr. Edward Arnold). We can also supply recombinant HIV-1 RT to Dr. Parniak as needed. We have developed a system using a one-round HIV-1 vector to measure the effects of mutations in RT or in the genome on DNA synthesis in infected cells. The in vivo HIV-1 vector experiments have been designed so that we can follow specific steps in reverse transcription; this should make it possible to compare results obtained in vitro with purified mutant RT and the effects of these RT mutants on viral replication.
Showing the most recent 10 out of 25 publications